U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757204) titled 'An Open-label Long-term Safety Study of Buntanetap in Participants With AD' on July 31.
Brief Summary: This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.
Study Start Date: Sept. 21
Study Type: INTERVENTIONAL
Condition:
Alzheimer's Dementia (AD)
Intervention:
DRUG: buntanetap/posiphen
buntanetap 30 mg daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Annovis Bio Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....